Amwill Health Care Ltd is a derma-cosmetic company specializing in dermatological, cosmeceutical, and aesthetic products. It focuses on product formulation and development, outsourcing manufacturing and distribution to third-party agencies to streamline operations.

The company plans to raise capital through an Initial Public Offering, offering 62,00,000 equity shares, which includes a fresh issue of 50,00,000 shares and an offer for sale of 12,00,000 shares.

Their product portfolio is categorized into generic dermatological solutions and specific problem-solving drugs, reflecting a strategic focus on dermatological innovation.

Key products include XL-HYDRA, a facial moisturizer, and Fin-XL Pro Gel, a hair-care product, signifying their commitment to developing diverse personal care solutions.

Amwill Health Care has partnered with Amderma Healthcare LLP for a structured storage and distribution chain, highlighting their focus on efficient supply chain management.